Compare Stocks: THTX, MDXG, NVCT, and EIKN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EIKN Eikon Therapeutics	$12.01 +3.1%	$10.23	$7.90 ▼ $17.40	$631.02M	N/A	377,123 shs	1.41 million shs
MDXG MiMedx Group	$4.45 +2.5%	$4.08	$3.03 ▼ $7.97	$632.60M	1.45	1.52 million shs	1.16 million shs
NVCT Nuvectis Pharma	$23.33 +11.6%	$19.02	$5.55 ▼ $29.27	$681.28M	-0.26	208,649 shs	362,726 shs
THTX Theratechnologies	$3.42 +0.9%	$3.35	$2.24 ▼ $3.40	$157.21M	0.51	506,857 shs	3.27 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EIKN Eikon Therapeutics	+11.27%	+13.88%	+19.24%	+9.29%	+1,164,999,900.00%
MDXG MiMedx Group	+3.58%	+0.46%	+0.93%	+14.51%	-39.64%
NVCT Nuvectis Pharma	+9.59%	+7.73%	+9.25%	+96.71%	+224.19%
THTX Theratechnologies	0.00%	0.00%	0.00%	0.00%	+5.52%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EIKN Eikon Therapeutics	$12.01 +3.1%	$10.23	$7.90 ▼ $17.40	$631.02M	N/A	377,123 shs	1.41 million shs
MDXG MiMedx Group	$4.45 +2.5%	$4.08	$3.03 ▼ $7.97	$632.60M	1.45	1.52 million shs	1.16 million shs
NVCT Nuvectis Pharma	$23.33 +11.6%	$19.02	$5.55 ▼ $29.27	$681.28M	-0.26	208,649 shs	362,726 shs
THTX Theratechnologies	$3.42 +0.9%	$3.35	$2.24 ▼ $3.40	$157.21M	0.51	506,857 shs	3.27 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EIKN Eikon Therapeutics	+11.27%	+13.88%	+19.24%	+9.29%	+1,164,999,900.00%
MDXG MiMedx Group	+3.58%	+0.46%	+0.93%	+14.51%	-39.64%
NVCT Nuvectis Pharma	+9.59%	+7.73%	+9.25%	+96.71%	+224.19%
THTX Theratechnologies	0.00%	0.00%	0.00%	0.00%	+5.52%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EIKN Eikon Therapeutics	2.38	Hold	$25.00	108.16% Upside
MDXG MiMedx Group	2.71	Moderate Buy	$8.43	89.41% Upside
NVCT Nuvectis Pharma	2.33	Hold	$35.00	50.02% Upside
THTX Theratechnologies	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest THTX, MDXG, NVCT, and EIKN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	MDXG MiMedx Group	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$8.00
8/17/2026	MDXG MiMedx Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$8.00
8/14/2026	EIKN Eikon Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Underperform	$5.00 ➝ $4.00
8/13/2026	MDXG MiMedx Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/5/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/3/2026	EIKN Eikon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E-) ➝ Sell (E)
7/6/2026	NVCT Nuvectis Pharma	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$33.00
7/6/2026	NVCT Nuvectis Pharma	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $33.00
6/22/2026	NVCT Nuvectis Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$13.00 ➝ $39.00
6/12/2026	NVCT Nuvectis Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$10.00 ➝ $13.00
6/5/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	$8.61 per share	N/A
MDXG MiMedx Group	$418.63M	1.55	$0.57 per share	7.83	$1.48 per share	3.01
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.28 per share	N/A
THTX Theratechnologies	$84.38M	1.86	N/A	N/A	($0.55) per share	-6.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EIKN Eikon Therapeutics	-$324.25M	-$4.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MDXG MiMedx Group	$48.58M	$0.04	111.28	26.18	N/A	1.76%	12.09%	9.22%	11/4/2026 (Estimated)
NVCT Nuvectis Pharma	-$26.44M	-$1.31	N/A	N/A	N/A	N/A	-184.25%	-105.24%	11/3/2026 (Estimated)
THTX Theratechnologies	-$8.31M	-$0.19	N/A	48.84	N/A	-10.85%	N/A	-9.83%	N/A

Latest THTX, MDXG, NVCT, and EIKN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	EIKN Eikon Therapeutics	-$1.61	-$1.63	-$0.02	-$1.63	N/A	N/A
8/4/2026	Q2 2026	NVCT Nuvectis Pharma	-$0.2620	-$0.30	-$0.0380	-$0.30	N/A	N/A
7/29/2026	Q2 2026 & M&A announcement	MDXG MiMedx Group	-$0.0495	-$0.05	-$0.0005	-$0.10	$63.46 million	$64.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EIKN Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A
MDXG MiMedx Group	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EIKN Eikon Therapeutics	N/A	9.89	9.89
MDXG MiMedx Group	0.07	5.33	4.79
NVCT Nuvectis Pharma	N/A	1.68	1.68
THTX Theratechnologies	N/A	0.84	0.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EIKN Eikon Therapeutics	N/A
MDXG MiMedx Group	79.15%
NVCT Nuvectis Pharma	96.77%
THTX Theratechnologies	N/A

Insider Ownership

Company	Insider Ownership
EIKN Eikon Therapeutics	N/A
MDXG MiMedx Group	2.50%
NVCT Nuvectis Pharma	28.55%
THTX Theratechnologies	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EIKN Eikon Therapeutics	384	54.17 million	N/A	N/A
MDXG MiMedx Group	870	145.76 million	142.12 million	Optionable
NVCT Nuvectis Pharma	8	32.58 million	23.28 million	Not Optionable
THTX Theratechnologies	140	45.98 million	N/A	Optionable

THTX, MDXG, NVCT, and EIKN Headlines

Recent News About These Companies

Theratechnologies Announces Completion of Acquisition by Future Pak

September 25, 2025 | globenewswire.com

Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak

September 16, 2025 | financialpost.comF

Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak

September 16, 2025 | globenewswire.com

Theratechnologies shareholders approve proposed acquisition by Future Pak

September 12, 2025 | msn.com

Theratechnologies Shareholders Approve Acquisition by Future Pak Affiliate

September 12, 2025 | tipranks.com

Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak

September 12, 2025 | financialpost.comF

Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak

September 12, 2025 | globenewswire.com

Theratechnologies announces availability of EGRIFTA WR

September 6, 2025 | msn.com

Theratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy

September 5, 2025 | globenewswire.com

Theratechnologies Announces Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Shareholders Vote “FOR” the Proposed Plan of Arrangement with Future Pak

September 2, 2025 | globenewswire.com

Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak

August 18, 2025 | globenewswire.com

Theratechnologies Reports Financial Results for the Second Quarter 2025

July 9, 2025 | globenewswire.com

Theratechnologies: Beyond GLP-1s - Is Tesamorelin's Exit A Sign Of New Metabolic Opportunities?

July 7, 2025 | seekingalpha.com

Future Pak to buy Theratechnologies for $254 million

July 4, 2025 | thepharmaletter.comT

Theratechnologies Stock (NASDAQ:THTX), Insider Trading Activity

July 3, 2025 | benzinga.com

Theratechnologies Inc. (THTX) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

Theratechnologies Stock Short Interest Report | NASDAQ:THTX - Benzinga

July 3, 2025 | benzinga.com

Theratechnologies shareholders should take the deal, Research Capital says

July 3, 2025 | cantechletter.comC

Theratechnologies to be bought by CB Biotechnology for $254M

July 3, 2025 | msn.com

Theratechnologies to Announce Second Quarter 2025 Financial Results

July 3, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

THTX, MDXG, NVCT, and EIKN Company Descriptions

Eikon Therapeutics NASDAQ:EIKN

$12.01 +0.36 (+3.09%)

Closing price 04:00 PM Eastern

Extended Trading

$12.52 +0.51 (+4.20%)

As of 07:30 PM Eastern

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers. Our Chair and Chief Executive Officer, Dr. Roger M. Perlmutter, M.D., Ph.D., and our Chief Medical Officer, Dr. Roy Baynes, M.D., Ph.D., together have a proven track record of identifying, developing, and commercializing some of the most impactful drugs ever brought to market, including pembrolizumab, currently the world’s best-selling oncology therapeutic and arguably the most important anti-neoplastic agent ever introduced into clinical practice. While Drs. Perlmutter and Baynes’ track records do not provide a guarantee of future clinical success, and any products developed by us may not achieve the regulatory or commercial success of products that Drs. Perlmutter and Baynes were previously involved in developing, their experience provides valuable insight and strategic guidance to our drug development efforts. Our broader leadership team consists of former senior leaders at global pharmaceutical companies, who have successfully collaborated across several decades on the discovery, development, and commercialization of over 100 new molecular entities. Our strategy centers around deploying our technology platform, including our proprietary single molecule tracking, or SMT, system, to develop internally-derived novel therapies, while also leveraging the deep expertise of our management team to opportunistically in-license promising assets. Our most advanced product candidate, EIK1001, a toll-like receptor, or TLR, 7/8 dual-agonist, is currently in a global Phase 2/3 registrational trial in combination with pembrolizumab for the treatment of patients with advanced melanoma. This Phase 2/3 trial is designed to proceed to completion, subject to interim analysis by a data monitoring committee, and to form the basis for registration. We are also evaluating EIK1001 in combination with both pembrolizumab and histology appropriate chemotherapy for the treatment of patients with non-small cell lung cancer, or NSCLC, in a Phase 2 trial, as well as a Phase 2/3 registrational trial for which we recently initiated site selection. We are also conducting Phase 1/2 trials of each of our selective PARP1 inhibitor product candidates, EIK1003 and EIK1004, in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant candidate EIK1004, to address brain metastases and primary brain malignancies. In addition, we have recently initiated a Phase 1/2 trial in patients with advanced solid tumors for EIK1005, our Werner, or WRN, helicase inhibitor that emerged through internal research using our technology platform, which will ultimately be evaluated for the treatment of patients with microsatellite instability-high, or MSI-high, tumors. We were incorporated in Delaware in July 2019. Our principal executive offices are located in Millbrae, California.

MiMedx Group NASDAQ:MDXG

$4.45 +0.11 (+2.53%)

Closing price 04:00 PM Eastern

Extended Trading

$4.46 +0.00 (+0.11%)

As of 07:59 PM Eastern

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Nuvectis Pharma NASDAQ:NVCT

$23.33 +2.42 (+11.57%)

Closing price 04:00 PM Eastern

Extended Trading

$23.74 +0.42 (+1.78%)

As of 07:30 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Theratechnologies NASDAQ:THTX

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest THTX, MDXG, NVCT, and EIKN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest THTX, MDXG, NVCT, and EIKN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

THTX, MDXG, NVCT, and EIKN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

THTX, MDXG, NVCT, and EIKN Company Descriptions

Eikon Therapeutics NASDAQ:EIKN

MiMedx Group NASDAQ:MDXG

Nuvectis Pharma NASDAQ:NVCT

Theratechnologies NASDAQ:THTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest THTX, MDXG, NVCT, and EIKN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest THTX, MDXG, NVCT, and EIKN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

THTX, MDXG, NVCT, and EIKN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

THTX, MDXG, NVCT, and EIKN Company Descriptions

Eikon Therapeutics NASDAQ:EIKN

MiMedx Group NASDAQ:MDXG

Nuvectis Pharma NASDAQ:NVCT

Theratechnologies NASDAQ:THTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools